Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan brain cancer. Its lead product candidate, Tolimidone, is a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTX240, for the treatment of gastrointestinal stromal tumors. In addition, the company offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release therapeutics; MidaSolve, nanotechnology used to dissolve insoluble drugs so that they can be administered in liquid form directly and locally into tumours; and MidaCore, a gold nanoparticle used for targeting sites of disease. It has collaboration agreements with Janssen and Melior. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.…
European Equities Traded in the US as American Depositary Receipts Rise Marginally in Friday Trading
Biodexa Pharmaceuticals (NASDAQ: BDRX) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 11 employees.
The shares were at 1.875 USD on 20 November 2026, down 99.1% over 52 weeks. Its 52-week range is 1.850 USD to 357.60 USD: the price is 99.5% below the high and 1.4% above the low.
Its market capitalisation is 982.95K USD.
Biodexa Pharmaceuticals reports return on equity of -56.0% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 3.23M GBP. Its Piotroski F-score is 4 out of 9, an average reading of its financial health.